
FDA expedites review of Sanofi’s Type 1 diabetes drug
The US Food and Drug Administration (FDA) has accepted Sanofi’s Stage 3 Type 1 diabetes drug, Tzield, for expedited review. Tzield delays the progression of Stage 3 Type 1 diabetes (T1D) in patients eight years or older who have recently been diagnosed. Sanofi’s drug received expedited review… Read More













